mresvia - Search News

Order byBest matchMost fresh

News

Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA

Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.

Continue reading

PharmExec · 1d

FDA Approves Expanded Indication for Moderna’s Respiratory Syncytial Virus Vaccine mRESVIA

FDA clears Moderna’s RSV vaccine for use in people ages 18 to 59

1don MSN

Moderna falls on doubts over new CDC panel's backing of RSV vaccine

Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back the use of the company's ...

Moderna's RSV shot gets US nod for use in younger adults

Pfizer's RSV shot Abrysvo was cleared by the FDA last October for the 18 to 59 age group, extending its 2023 approval in the ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results